ClinicalTrials.gg
Sign In

Leiomyosarcoma clinical trials

The registry lists 177 studies for Leiomyosarcoma across more than 10 countries. 35 are recruiting or about to start. 73 of them are mainly about Leiomyosarcoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-04.

Get an email when these change. Save the Leiomyosarcoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
87
Recruiting
31
Terminated
21
Active, not recruiting
14
Status unknown
13
Withdrawn
6

Phase

Phase 2
107
Phase 1
40
Phase 3
23
Early Phase 1
1

Where

United States
108
France
27
United Kingdom
22
Spain
19
Germany
19
Canada
16

Who runs them

National Cancer Institute (NCI) (20) · European Organisation for Research and Treatment of Cancer - EORTC (15) · Memorial Sloan Kettering Cancer Center (10) · M.D. Anderson Cancer Center (6) · Eli Lilly and Company (3) · Dana-Farber Cancer Institute (3) · Gynecologic Oncology Group (3) · UNICANCER (3)

What is being tested here

Drugs under test in Leiomyosarcoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Doxorubicin3517
Trabectedin2312
Liposomal doxorubicin204
Ifosfamide169
Pazopanib118
Selinexor102
Dacarbazine112
Peposertib101
Ivonescimab101
Abemaciclib101

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 4 open · Immune checkpoint inhibitors 3 open · Alkylating agents 2 open · Antimitotic agents 7 · HDAC inhibitors 5

Coming up

4phase 3 studies under way
15studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 31 Leiomyosarcoma studies recruiting now, 25 (81%) set no upper age limit and 4 (13%) stop at 75 or younger. 6 (19%) take children under 18. 3 (10%) are for women only and 0 (0%) for men only; 1 (3%) take healthy volunteers.

Recruiting studies that take each age, of 31
AgeWomenMen
104 (13%)4 (13%)
1830 (97%)27 (87%)
3030 (97%)27 (87%)
4029 (94%)26 (84%)
5029 (94%)26 (84%)
6530 (97%)27 (87%)
7529 (94%)26 (84%)
8527 (87%)25 (81%)

Across all 177 studies, recruiting or not: 11% stop at 75 or younger and 2% at 65; 23% take children; 16% are for women only and 0% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Leiomyosarcoma studies take

Of 41 phase 2 interventional studies under Leiomyosarcoma, half reached primary completion within 62 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 262 mo35–80 · 41 studies—61 mo35–80 · 38 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 177. Browse all 177 → or search them.